At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Closed 03-03 16:08:29
14.420
-0.840
-5.50%
High15.410Low14.320Vol3.02M
Open15.260D1 Closing15.260Amplitude7.14%
Mkt Cap15.30BTradable Cap15.30BTotal Shares1.06B
T/O44.47MT/O Rate0.28%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Ascletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities
Bulletin Express  ·  15:22
Ascletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities
Hong Kong Market Enters Era of Pricing Power Stratification as Mainland's 1.41 Trillion HKD Southbound Flows Anchor Market While Korean Retail Investors Ignite Speculative Activity
Stock News  ·  02-13
Hong Kong Market Enters Era of Pricing Power Stratification as Mainland's 1.41 Trillion HKD Southbound Flows Anchor Market While Korean Retail Investors Ignite Speculative Activity
Assessing Ascletis Pharma (SEHK:1672) Valuation After New Obesity And Acne Pipeline Updates
Simply Wall St.  ·  02-11
Assessing Ascletis Pharma (SEHK:1672) Valuation After New Obesity And Acne Pipeline Updates
Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies
MT Newswires Live  ·  02-11
Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies
BRIEF-Ascletis Pharma Selects Asc36 For Clinical Development
Reuters  ·  02-11
BRIEF-Ascletis Pharma Selects Asc36 For Clinical Development
Ascletis Pharma: Expects to Submit Ind to FDA for Asc36 Oral Tablets for Treatment of Obesity in Q2 2026
THOMSON REUTERS  ·  02-11
Ascletis Pharma: Expects to Submit Ind to FDA for Asc36 Oral Tablets for Treatment of Obesity in Q2 2026
Ascletis Pharma Inc. (1672) Announces Oral Amylin Receptor Peptide Agonist ASC36 for Clinical Development
Bulletin Express  ·  02-11
Ascletis Pharma Inc. (1672) Announces Oral Amylin Receptor Peptide Agonist ASC36 for Clinical Development
ASCLETIS-B Selects Oral Amylin Receptor Agonist Peptide ASC36 for Clinical Development
Stock News  ·  02-11
ASCLETIS-B Selects Oral Amylin Receptor Agonist Peptide ASC36 for Clinical Development
Ascletis Pharma Inc - Selects Asc36 for Clinical Development
THOMSON REUTERS  ·  02-11
Ascletis Pharma Inc - Selects Asc36 for Clinical Development
Ascletis Pharma Selects Oral Amylin Agonist ASC36 for Clinical Development
Reuters  ·  02-11
Ascletis Pharma Selects Oral Amylin Agonist ASC36 for Clinical Development
Ascletis Pharma (01672) Announces 69.256 Million New Shares Issued and Provides Share Repurchase Update
Bulletin Express  ·  02-10
Ascletis Pharma (01672) Announces 69.256 Million New Shares Issued and Provides Share Repurchase Update
Ascletis Pharma (1672) Announces Completion of New Share Placement Under General Mandate
Bulletin Express  ·  02-10
Ascletis Pharma (1672) Announces Completion of New Share Placement Under General Mandate
ASCLETIS-B Completes Placement of 69.256 Million Shares, Raising Approximately HK$835 Million Net Proceeds
Stock News  ·  02-10
ASCLETIS-B Completes Placement of 69.256 Million Shares, Raising Approximately HK$835 Million Net Proceeds
Ascletis Pharma platziert 69,26 Millionen neue Aktien bei Investoren
Reuters  ·  02-10
Ascletis Pharma platziert 69,26 Millionen neue Aktien bei Investoren
ASCLETIS-B (01672) Rises Over 6% Again as ASC30 Accelerates Global Phase III Trials; Analysts See High BD Potential
Stock News  ·  02-10
ASCLETIS-B (01672) Rises Over 6% Again as ASC30 Accelerates Global Phase III Trials; Analysts See High BD Potential
HK Movers | HK's Biotech Shares Soar. ImmuneOnco up 7%; Zai Lab, Remegen, Innovent Bio up 5%; Ascletis, Wuxi Bio up 4%
Tiger Newspress  ·  02-10
HK Movers | HK's Biotech Shares Soar. ImmuneOnco up 7%; Zai Lab, Remegen, Innovent Bio up 5%; Ascletis, Wuxi Bio up 4%
HK Movers | Ascletis Pharma Stock up 8% After GIC Invests US$100M in Company, Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Tiger Newspress  ·  02-09
HK Movers | Ascletis Pharma Stock up 8% After GIC Invests US$100M in Company, Anchoring Long-Term Capital in China's Core Innovative Drug Assets
ASCLETIS-B Shares Surge Nearly 9% in Morning Session Following GIC's HK$781 Million Stake Increase
Stock News  ·  02-09
ASCLETIS-B Shares Surge Nearly 9% in Morning Session Following GIC's HK$781 Million Stake Increase
Tirzepatide Crowned as New "Blockbuster Drug King" with Rapid Commercial Value Release Expected for Weight Loss Medications
Stock News  ·  02-05
Tirzepatide Crowned as New "Blockbuster Drug King" with Rapid Commercial Value Release Expected for Weight Loss Medications
Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?
Simply Wall St.  ·  02-04
Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--